Key terms
About ADCT
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ADCT news
Mar 15
9:50pm ET
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 13
1:30pm ET
Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT) and Cresco Labs (OtherCRLBF)
Mar 13
12:00pm ET
ADC Therapeutics falls -13.5%
Mar 13
10:00am ET
ADC Therapeutics falls -20.2%
Mar 13
9:47am ET
ADC Therapeutics falls -15.3%
Mar 13
7:11am ET
ADC Therapeutics expects cash runway to extend into 4Q25
Mar 13
7:10am ET
ADC Therapeutics reports Q4 adjusted EPS (97c), consensus (50c)
Mar 06
6:37am ET
ADC Therapeutics: A Strong Buy on Promising Trial Results and Financial Stability
Mar 05
9:32am ET
ADC Therapeutics Shares Strategic Insights at Conferences
Feb 29
4:43pm ET
ADC Therapeutics Launches New Employee Incentive Plan
Feb 26
7:36am ET
RBC Capital Remains a Buy on ADC Therapeutics (ADCT)
Feb 20
6:27am ET
Buy Rating Affirmed for ADC Therapeutics with Raised Price Target Amid Promising Clinical Trials and Strong Balance Sheet
Feb 20
6:17am ET
ADC Therapeutics price target raised to $9 from $3 at H.C. Wainwright
Feb 14
12:00pm ET
ADC Therapeutics rises 14.7%
Jan 25
4:07am ET
ADC Therapeutics Strikes Key Deal with Redmile Group
Jan 05
8:47pm ET
RBC Capital Keeps Their Buy Rating on ADC Therapeutics (ADCT)
Jan 05
6:31am ET
Optimistic Outlook: Buy Rating for ADC Therapeutics Amid Anticipated Clinical Milestones and Strong Financials
Jan 04
7:16am ET
ADC Therapeutics regains compliance with NYSE continued listing standards
Jan 04
7:07am ET
ADC Therapeutics provides business updates
No recent news articles are available for ADCT
No recent press releases are available for ADCT
ADCT Financials
Key terms
Ad Feedback
ADCT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ADCT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range